NEW YORK (GenomeWeb News) – Qiagen will use a database and software, as well as clinical samples, from the Center for Molecular Medicine in research aimed at developing biomarkers for breast cancer and other women’s health issues, the company said today.
 
The agreement gives Qiagen access to CMM’s XenoBase software and database, which was developed by CMM’s partner, the Van Andel Research Institute, to “identify clinically actionable associations between diseases, biomarkers and treatments,” the company said. 
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.